Want to create interactive content? It’s easy in Genially!
NuRenal Intro - INVESTORS 2024
Luis Valdes
Created on October 21, 2024
Start designing with a free template
Discover more than 1500 professional designs like these:
Transcript
START
Shaping the Future of Dialysis Care
07 · Metrics
06 · Market Insights
05 · Customers & Case Studies
04 · Business Model & Stategy
03 · Intro
02 · Dialysis Industry
01 · Market Analysis
nurenal software
NuRenal is designed to streamline and optimize the operations of dialysis organizations, with user-friendly and powerful tools.
INDEX
MARKET ANALYSIS
40%
15%
6.7%
11.7%
26.7%
Market growth
5%
4.5%
7%
3.5%
4%
Middle East & Africa
Latin America
Asia-Pacific
GLOBAL DIALYSIS PATIENTS
3 MILLION
Europe
North America
Market analysis
GLOBAL Market Breakdown
450k
200K
350K
1.2M
800k
41,712
Satellite
Dialysis Clinic Inc.
MEDIUM
8,209
14,969
Independent
LARGE
source: STATISTICS.COM
total u.S. patients
519,242
17,018
25,327
DaVita
Fresenius
MEDIUM
LARGE
204,000
208,007
Innovative Renal Care
U.S. Renal Care
BROKEN BY PROVIDER TYPE
u.s. dialysis patients
MEDIUM
LARGE
NUMBER OF patients:
Annually
SCALABLE BUSINESS MODEL
20K
us PATIENT Growth
3 Millionpatients
Payment adjustment
Shift Toward Home Dialysis
Unmet Needs in Dialysis Care
2025
MARKET PROJECTION & OPPORTUNITY
PERSONALIZED CARE
PAYMENT MODELS
early intervation& preventive care
THE FUTUREOF DIALYSIS
HOME DIALYSIS INNOVATIONS &TELEHEALTH
VALUE BASED CARE & TECHNOLOGICAL ADVANCEMENTS
ai powered analytics & monitoring
PORTABLE & WEARABLE DIALYSIS DEVICES
SLIDE PREVIOUSLY HIDDEN*
market analysis
Home dialysis will play a pivotal role, with wearable technologies and AI transforming patient care.
Providers that embrace personalized care and value-based models will thrive in the evolving landscape.
conclusion & key takeaways
The U.S. dialysis market will continue to grow, driven by rising patient numbers and innovative technologies.
BUSINESS MODEL & STRATEGY
(ALL INCLUSIVE)
(ALL INCLUSIVE)
(ALL INCLUSIVE)
(ALL INCLUSIVE)
$20moPER PATIENT
(ALL INCLUSIVE)
$20moPER PATIENT
2.5 % of total clinic revenue
CKD
2.5 % of total clinic revenue
(PER MODULE)
$15moper user
$26MOPER PATIENT
BILLING
EMR
ERP
Based on monthly subscription plans with 3 years contracts
BUSINESS MODEL
CUSTOMERS
PATIENT REACH
200
572
45
190
271
1.9K
305
417
400
Total Centers & Patients:65 CENTERS & 1,400 PATIENTS
Atlantis Health Care Group
American Kidney Center
RENVIVA
Lakes Dialysis
Kidney Kare
PhysiciansDialysis
Physicians Choice
Central Florida Kidney Centers
KidneySpa
BETA PROGRAM
CURRENT & UPCOMING REACH
CASE STUDIES
Streamlining Operations with
KIDNEYspa
Patient Schedule
Replaced complex manual scheduling with an automated, real-time system. Front desk saves 236 hours yearly Managers save 65 hours yearly
Physicians dialysis
Compliance Monitoring
Replaced paper-based logs resulted in timely and accurate patient care while simplifying audit procedures.
KIDNEY kare
Employee Engagement
BETA PROGRAMS
CASE STUDIES
Tranforming their employee documentation and compliance management processes resulted in a Zero Deficiencies ACHA inspection.
COMPETITOR ANALYSIS
PayorManagement
Cost Reports
Verification &Authorization
Coordinationof Benefits
Intake &Registration
Advanced Analytics
PatientEngagement
ProtocolManagement
Physician Rounding
Clinical Management
Document& Contracts
Compliance& Regulatory
SOP / Policies & Procedures
Procurement& Inventory
Employee Engagement& Training
RCM
EMR
ERP
COMPETITOR ANALYSIS
METRICS
NuRenal RCM
NuRenal erp
NuRenal EMR
EBITDA
EXPENSE
REVENUE
SKYROCKETING GROWTH ESTIMATE
10 YEARS GROWTH
SLIDE PREVIOUSLY HIDDEN*
10 YEAR GROwth
EXPECTED PATIENT GROWTH
By 2026, NuRenal could reach a valuation of $38.23 million with 6,000 U.S. patients and up to $382.32 million once we scale to 50,000 global patients, assuming less than 2% of market penetration.
Leadershop, Sales and Data Analytics
Expand sales and increase NuRenal ERP implantation
EMR & RCM
HIRE KEY STAFF
ERP PHASE 2
SOFTWAREDEVELOPMENT
We are looking for $2 Millions in funds for a 10% equity stake in our company in order to accelerate the roll out of NuRenal ERP and hire key staff to finish development of our NuRenal EMR and RCM products
THE ASK
5 YEARS
INVESTMENTLENGHT
57.15%
858.46%
$8,584,643
ANNUALIZED ROI
ROI
INVESTMENTGAIN
Your estimated Annual Return of Investment is 57.15%!
The investment gain
hello@nurenal.com
NuRenal has the potential to significantly increase its valuation by focusing on key growth drivers such as accelerating patient base growth, launching high-value products (EMR and RCM), expanding internationally, and investing in AI capabilities.
If you have questions or would like to invest in NuRenal, please don't hesitate to reach out to us.